01 2023 01 16 BDD Poster guselkumab Ra S

Exploring the exposure-response relationship of Guselkumab in chronic plaque Psoriasis: Preliminary results

Rani Soenen

Open PDF

02 2023 01 11 BDD Poster Lisa S portrait

Blocking Interleukin-17 in Psoriasis: Real-world experience from the PsoPlus cohort

Lisa Schots

Open PDF

03 Prevalence of comorbidities in the UZ Leuven psoriasis cohort

Psoriasis in the Belgian population: prevalence of comorbidities

Heleen Cokelaere
Tom Hillary

Open PDF

04 BDD2023 Poster 4

Nectin-4-directed oncologic therapies, what to expect as a dermatologist?

Evelyn Meulewaeter
Linda
Temmerman

Open PDF

05 BDD2023 Poster PGD UZL

The impact of the COVID-19 pandemic on the incidence and thickness of cutaneous melanoma in Belgium

P.G. Demaerel

Open PDF

06 Poster BDD

A cohort study of older adults receiving Mohs micrographic surgery for a facial basal cell carcinoma: should we waive MMS in certain patients?

Laura Van Coile

Open PDF

07 Poster BDD190123

Vitamin D receptor expression in cutaneous melanoma tissue: prognostic properties and influencing factors

Julie De Smedt

Open PDF

08 poster BDD2023 08

Acute pancreatitis induced by topical isotretinoin, an unprecedented association

Thomas Damsin

Open PDF

09 BDD poster Prognostic Value Disease Activity Signs Vitiligo n9

Prognostic value of the Vitiligo disease activity signs

Liesbeth Delbaere

Open PDF

10 BDD 2023 POETYK BSA s PG Ax BSA Encore Poster Bristol Myers Squibb Lambert

Deucravacitinib, an oral, selective, Allosteric Tyrosine Kinase 2 inhibitor, versus placebo and Apremilast in moderate to severe plaque Psoriasis: Analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials

Jo Lambert

Open PDF

11 Key secondary endpoints at Month 12 3rd Interim BDD 2023 Final draft 18 Jan2023

Initial report on the month 12 results from the Psoriasis study of health outcomes (PSoHO) for patients with moderate-to-severe Psoriasis treated with biologics in the real-world setting

L. Ghys

Open PDF

12 Multiple CBA global Ps O improv in all 3 measures BDD 2023 18 Jan2023

Ixekizumab demonstrates comprehensive Psoriasis clearance in patients with moderate-to-severe Psoriasis with scalp, nail, and/or palmoplantar involvement: UNCOVER-1, -2 trials through 5 years

L. Ghys

Open PDF

13 Poster BDD 2023 nr13 REDISCOVER Final Version Hillary et al

Disease severity and implementation of the Belgian T2T guidelines in moderate-to-severe plaque Psoriasis: results from the Belgian REDISCOVER study

L.F.E. Ghys

Open PDF

14 Poster number 14 BDD 2023 JAHO JAIR Trajectories Final Draft 20 Jan2023

Trajectories for scalp hair regrowth in patients with severe Alopecia Areata treated with Baricitinib

L. Ghys

Open PDF

15 Poster number 15 BDD 2023 JAHN 2yr Qo L Final draft 20 Jan 2023

Maintained improvement in patient rated outcomes with Baricitinib 4-mg in adults with moderate to severe Atopic Dermatitis who were treated for up to 104 weeks in randomised controlled trials

L. Ghys

Open PDF

16 Poster number 16 BDD 2023 AD Annual Safety 2022 Final draft 20 Jan 2023

Safety of Baricitinib for the treatment of Atopic Dermatitis over a median of 1.6 and up to 3.9 years treatment: An updated integrated analysis of 8 clinical trials

L. Ghys

Open PDF

17 BDD 2023 SUNNY Wk16 Poster 17

Secukinumab in moderate to severe Hidradenitis Suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials

Farida Benhadou

Open PDF

Verder lezen?

Word nu lid van de Koninklijke Belgische Vereniging voor Dermatologie en Venerologie (KBVDV) en de Beroepsvereniging der Belgische Dermatologen en Venerologen (BBDV)!

Als lid van deze verenigingen geniet je tal van voordelen, waaronder toegang tot alle content van onze website en
de website van de Beroepsvereniging. Daarnaast betaal je een sterk verlaagd voordeeltarief voor de jaarlijkse Belgian Dermatology days én ontvang je regelmatig newsletters met relevante informatie over de uitoefening van ons beroep. Bovendien krijg je ook een korting op de website van contactallergie (met oa. allergenenlijsten) en een polis burgerlijke aansprakelijkheid beroep, speciaal ontwikkeld voor onze discipline, aan zeer gunstige voorwaarden.